The combined company has a strong institutional investor syndicate and a compelling pipeline candidate. Traders should watch for stockholder approval of Series A conversion and warrants, as well as IND-enabling study progress. The stock may see volatile re-rating as the market digests the new pipeline and dilution.
Price Chart
Executive Summary
Adial Pharmaceuticals acquires Azora Therapeutics and secures up to $64M in private placement, pivoting to a colon-targeted AhR agonist (AT177) for ulcerative colitis. Existing shareholders will be diluted to ~7.7% post-transaction. The deal is transformative for the micro-cap biotech, providing funding through Phase 1 data readout expected in 2027.
Key Financial Metrics
Key Facts
- Acquired Azora Therapeutics for stock; legacy Adial holders will own ~7.7% post-transaction.
- Up to $64M private placement led by Coastlands Capital, with $32M upfront.
- Lead asset AT177 is a colon-targeted AhR agonist for ulcerative colitis, in IND-enabling studies.
- Wendy Young appointed to board; she brings 32+ years of drug discovery experience from Genentech.
Financial Impact
Up to $64M gross proceeds from private placement; upfront $32M at $2.7489 per pre-funded warrant.
Risk Factors
- Massive dilution: legacy Adial holders reduced to ~7.7% ownership.
- Clinical risk: AT177 is in early stages; Phase 1 failure would be material.
- Stockholder approval required for conversion of preferred and warrants; vote outcome uncertain.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3310671 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 10-Q/A | $4.11 | awaiting T+60 | — | $3.68 (+10.46%) |
Oct 20, 2026 6d ago | S-3/A | $4.11 | awaiting T+60 | — | $3.68 (+10.46%) |
Oct 16, 2026 10d ago | DEFA14A | $3.62 | awaiting T+60 | — | $3.68 (−1.66%) |
Oct 16, 2026 10d ago | 8-K | $3.62 | awaiting T+60 | — | $3.68 (−1.66%) |
Sep 30, 2026 26d ago | Press Release | $4.13 | awaiting T+60 | — | $3.68 (−10.90%) |
Sep 18, 2026 5w ago | DEFA14A | $4.40 | awaiting T+60 | — | $3.68 (−16.36%) |
Sep 18, 2026 5w ago | 8-K | $4.40 | awaiting T+60 | — | $3.68 (−16.36%) |
Sep 16, 2026 5w ago | DEFA14A | $5.21 | awaiting T+60 | — | $3.68 (−29.37%) |
Sep 16, 2026 5w ago | 8-K | $5.21 | awaiting T+60 | — | $3.68 (−29.37%) |
Aug 17, 2026 10w ago | 8-K | $4.99 | awaiting T+60 | — | $3.68 (−26.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers